Taprenepag isopropyl

Modify Date: 2024-01-05 08:21:09

Taprenepag isopropyl Structure
Taprenepag isopropyl structure
Common Name Taprenepag isopropyl
CAS Number 1005549-94-9 Molecular Weight 520.60000
Density N/A Boiling Point N/A
Molecular Formula C27H28N4O5S Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Taprenepag isopropyl


Taprenepag isopropyl is a highly selective EP2 receptor agonist.

 Names

Name propan-2-yl 2-[3-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]phenoxy]acetate
Synonym More Synonyms

 Taprenepag isopropyl Biological Activity

Description Taprenepag isopropyl is a highly selective EP2 receptor agonist.
Related Catalog
Target

EP2 Receptor

In Vivo Taprenepag isopropyl is a highly selective EP2 receptor agonist. Intraocular pressure (IOP) in the left, vehicle-dosed eye typically remains within the normal range. In the right (Taprenepag isopropyl-dosed) eye, IOP is reduced in all dose groups. In the high-dose group, IOP is reduced to the extent that it cannot be measured (<4mm Hg) on Days 22 and 29. There are no clinical signs or changes in body weight observed with any dose of Taprenepag isopropyl administration, and noocular findings occur for animals in the low-dose group (0.75 mg/day)[1].
Animal Admin Three year-old, male cynomolgus monkeys with body weights ranging from 2.6 to 5.0 kg are used in this study. Animals are dosed twice daily for 28 days in the right eye with Taprenepag isopropyl (0.75, 12, or 36 mg/day), and an equal volume of vehicle (containing cremophor, boric acid, BAC, and EDTA) is dosed in the left eye. An additional 2 monkeys are included in the high-dose group to assess recovery over a 28 day period. Toxicity outcomes are based on the assessment of clinical signs, body weight, ophthalmic examination, pupillary diameter, corneal staining, pachymetry, and noncontact specular microscopy. IOP is measured once during the predose phase and before dosing on Days 1, 8, 15, 22, and 29 of the dosing phase, then once during each week of the recovery period[1].
References

[1]. Yanochko GM, et al. Investigation of ocular events associated with taprenepag isopropyl, a topical EP2 agonist in development for treatment of glaucoma. J Ocul Pharmacol Ther. 2014 Jun;30(5):429-39.

 Chemical & Physical Properties

Molecular Formula C27H28N4O5S
Molecular Weight 520.60000
Exact Mass 520.17800
PSA 112.00000
LogP 5.06960
Storage condition 2-8℃

 Synonyms

unii-81ldp7xiyg
taprenepag isopropyl